Swedish and international institutional investors.
Moberg Pharma is a Swedish pharmaceutical company that commercializes proprietary, acquired and licensed products in the global market. Initially, the company specializes in the treatment of skin diseases but is now widening its scope. Moberg Pharma markets OTC brands in the U.S. and sells through distributors in more than 40 countries. Moberg Pharma has sales of SEK 157 million.
Directed issue to a number of Swedish and international institutional investors of SEK 60 million to fund acquisition of new marketed products and development projects.
HDR Partners identified potential investors, led negotiations and drafted a prospectus to be filed and approved by the Swedish Financial Supervisory Authority.